Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHOJ8W)

Drug Name

Isatoribine Drug Info

Synonyms

7-Thia-8-oxoguanosine; ANA245; 122970-40-5; UNII-2DNT962H92; ANA-245; 2DNT962H92; Immusine; Isatoribine [USAN:INN]; 7-TOG; Immunosine; Satoribine; N10146; 7-Deaza-7-thia-8-oxoguanosine; AC1L2HO7; SCHEMBL127980; AC1Q6N18; SCHEMBL12592999; CHEMBL2105116; ANA 245; TZYVRXZQAWPIAB-FCLHUMLKSA-N; ZINC8214713; 5-Amino-3-ribofuranosylthiazolo(4,5-d)pyrimidine-2,7(3H,6H)-dione; DB04860; 5-amino-3-(; A-d-ribofuranosyl)[1,3]thiazolo[4,5-d]pyrimidine-2,7(3h,4h)-dione; BRD-K87535339-001-01-6

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 2	[1]

Cross-matching ID

PubChem CID: 135409474
CAS Number: CAS 122970-40-5
TTD Drug ID: DMHOJ8W

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Toll-like receptor 7 (TLR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[3]
Hydroxychloroquine	DMSIVND	Chronic renal failure	GB61.Z	Approved	[4]
ANA773	DMSC8YW	Hepatitis C virus infection	1E51.1	Phase 2a	[5]
GS-9620	DMG5C8D	Hepatitis B virus infection	1E51.0	Phase 2	[6]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[7]
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[8]
LOXORIBINE	DMIV9ZE	Immune System disease	4A01-4B41	Phase 2	[9]
GSK2245035	DMBWPZJ	Asthma	CA23	Phase 2	[10]
AZD-8848	DM0M7QW	Allergic rhinitis	CA08.0	Phase 2	[11]
PF-4878691	DM24I0N	Melanoma	2C30	Phase 2	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00480831) A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g). U.S. National Institutes of Health.
2	Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
3	Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
4	TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
5	Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
6	Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
7	Company report (Iderapharma)
8	TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
9	The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
10	Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
11	Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
12	The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9.